Clinical translation

Z graphical abstract

Project-related publications

P1, P3, P4, P6, INF, Z

Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups

Hartmann AM, Bastian L, Barz MJ, Haas J, Amelunxen E, Ehm P, Lenk L, Kotrova M, Beder T, Steffen FD, Rauwolf K, Wolgast N, Bendig S, Bozzetti C, Alten J, Mondal M, Rademacher A, Heymann J, Walter W, Haferlach C, Ströh AS, Bergmann AK, Burmeister T, Gökbuget N, Bornhauser B, Bourquin JP, Brüggemann M, Schrappe M, Cario G, Baldus CD.

Hemasphere
2026
P1, P3, P4, Z, INF, P6

IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma

Horns JM, Beder T, Künstner A, Barz MJ, Bendig S, Bozzetti C, Chitadze G, Darzentas N, Iben K, Kotrova M, Martín-Subero JI, Mondal M, Neumann M, Fernandez Perez R, Ströh AS, Weßels W, Lenk L, Velten L, Böll B, Braitsch K, Bücklein VL, Duell J, Faul C, Fiedler W, Hanoun M, Janjetovic S, Klingler F, Knop S, Röllig C, Schwartz S, Spriewald BM, Steffen B, Wethmar K, Busch H, Gökbuget N, Baldus CD, Bastian L, Brüggemann M.

P1, Z

Results in pediatric T‐ALL patients treated in trial AIEOP‐ BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy

Cario G, Valsecchi MG, Conter V, Gotti G, Möricke A, Stanulla M, Vossen-Gajcy M, Lenk L, Stary J, Hrusak O, Dworzak M, Attarbaschi A, Barbaric D, Locatelli F, Bodmer N, Elitzur S, Silvestri D, Dalla-Pozza L, Fagioli F, Kulozik AE, Izraeli S, Rizzari C, Rademacher A, Buldini B, Bourquin JP, Zimmermann M, Schrappe M, Biondi A.

Hemasphere
2025
P1, P3, P6, P7, Z

The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis

Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM.

P1, P3, P4, Z, INF

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen BT, Hartmann AM, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller FJ, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus CD.

P1, P3, P4, INF, Z

The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age

Beder T, Hansen BT, Hartmann AM, Zimmermann J, Amelunxen E, Wolgast N, Walter W, Zaliova M, Antić Ž, Chouvarine P, Bartsch L, Barz MJ, Bultmann M, Horns J, Bendig S, Kässens J, Kaleta C, Cario G, Schrappe M, Neumann M, Gökbuget N, Bergmann AK, Trka J, Haferlach C, Brüggemann M, Baldus CD, Bastian L.

HemaSphere
2023
P1, P3, P4, INF, Z

UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

Bastian L, Hartmann AM, Beder T, Hänzelmann S, Kässens J, Bultmann M, Hoeppner MP, Franzenburg S, Wittig M, Franke F, Nagel I, Spielmann M, Reimer N, Busch H, Schwartz S, Steffen B, Viardot A, Döhner K, Kondakci M, Wulf G,  Wendelin K, Renzelmann A, Kiani A, Trautmann H, Neumann M, Gökbuget N, Brüggemann M, Baldus CD

Leukemia
2022
P1, Z

Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

Boer ML*, Cario G*, Moorman AV*, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliova M, Elitzur S, Cazzaniga G, Biondi A, Loh ML, Pieters R.

*equally contributing first authors.

The Lancet Haematology
2021
P1, P3, P4, Z

Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures

Schroeder MP, Bastian L, Eckert C, Gökbuget N, James AR, Tanchez JO, Schlee C, Isaakidis K, Häupl B, Baum K, Migueles Lozano OA, Kouidri K, Pan KT, Urlaub H, Schwartz S, Burmeister T, von Stackelberg A, Hoelzer D, Pfeiffer H, Rieger MA, Göllner S, Oellerich T, Horstmann M, Schrappe M, Wolf J, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Neumann M, Baldus CD

P1, P3, P4, Z

Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures

Schroeder MP, Bastian L, Eckert C, Gökbuget N, James AR, Tanchez JO, Schlee C, Isaakidis K, Häupl B, Baum K, Migueles Lozano OA, Kouidri K, Pan KT, Urlaub H, Schwartz S, Burmeister T, von Stackelberg A, Hoelzer D, Pfeiffer H, Rieger MA, Göllner S, Oellerich T, Horstman M, Schrappe M, Wolf J, Kirschner-Schwabe R, Brüggemann M, Müller-Tidow C, Serve H, Neumann M, Baldus CD

P1, P6, Z

IKZF1 plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M

TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol
2018

Researchers

Participating Institutes